Dataset of EGFRm NSCLC patients’ mutation profiles at resistance to osimertinib as 1st-line or 2nd-line treatment according to NGS based liquid biopsy tests.

In an approach to deepen the understanding and clarify possible mechanisms of osimertinib 1st-line resistance in comparison to the 2nd line we have examined NGS results of 30 patients who developed resistance to osimertinib.
Liquid biopsy technique (Guardant360) was used to monitor tumor dynamics in patients who were treated with osimertinib as 1st-line therapy (Group A, N=15) and patients who received osimertinib as 2nd-line therapy (Group B, N=15).
The raw data are composed of two tables presenting information of advanced EGFR mutated NSCLC patients who received treatment with osimertinib as 1st-line or 2nd-line therapy after developing resistance to early generation TKIs. Table 1 comprises data of 15 patients who received osimertinib as 1st-line and describes the patients’ gender, age at diagnosis, initial EGFR mutation (exon 19 deletion, L858R, or uncommon sensitizing EGFR mutations), initial other mutations found (if available), progression free survival (PFS) on osimertinib treatment and mutations at resistance to osimertinib detected by NGS liquid biopsy tests. Table 2 comprises data of 15 patients who received osimertinib as 2nd-line, previously treated with 1st/2nd-generation EGFR TKIs in whom p.T790M was diagnosed either in the tumor specimen or in the circulating tumor DNA (ctDNA) after testing it following the most recent disease progression. Table 2 includes the parameters described in table 1 in addition to first line TKI treatment (gefitinib, erlotinib, or afatinib) and PFS after 1st line TKI treatment.

为深化对奥希替尼（osimertinib）一线耐药潜在机制的认知并阐明其与二线耐药的差异，我们对30例发生奥希替尼耐药的患者的二代测序（NGS）结果进行了分析。
本研究采用液体活检技术（Guardant360）监测两类患者的肿瘤动态：一类为接受奥希替尼一线治疗的患者（A组，n=15），另一类为接受奥希替尼二线治疗的患者（B组，n=15）。
本研究的原始数据集包含两张表格，收录了经初代EGFR-TKI治疗后出现耐药、继而接受奥希替尼一线或二线治疗的晚期EGFR突变非小细胞肺癌（NSCLC）患者的相关信息。
表格1收录了15例接受奥希替尼一线治疗的患者数据，涵盖患者性别、确诊时年龄、初始EGFR突变类型（19号外显子缺失、L858R突变或罕见致敏性EGFR突变）、检出的初始其他突变（若存在）、奥希替尼治疗期间的无进展生存期（PFS），以及通过NGS液体活检检测到的奥希替尼耐药相关突变。
表格2收录了15例接受奥希替尼二线治疗的患者数据：此类患者既往接受过一代/二代EGFR-TKI治疗，且在最近一次疾病进展后的检测中，于肿瘤组织标本或循环肿瘤DNA（ctDNA）中检出p.T790M突变。
表格2除包含表格1的全部参数外，额外收录了一线TKI治疗类型（吉非替尼、厄洛替尼或阿法替尼）以及一线TKI治疗后的无进展生存期数据。